* NRX Pharmaceuticals Inc NRXP.OQ NRXP.O is expected
to report
results on November 14.
*
* Refinitiv's mean analyst estimate for NRX Pharmaceuticals
Inc
is for a loss of 14 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for NRX
Pharmaceuticals Inc is $3, above its last closing price
of $0.88.
This summary was machine generated November 11 at 17:00 GMT.
All figures in US dollars unless otherwise stated